Abstracts tagged "Gout and uric acid"

Abstract Number: 1128 • 2018 ACR/ARHP Annual Meeting
Impact of Urate-Lowering Therapy on the Risk of Cardiovascular Events and All-Cause Mortality Among Individuals with Gout
In Ah Choi¹, Hoyeon Jang² and Gil-Won Kang², ¹Division of Rheumatology, Department of Internal Medicine, Chungbuk National University Hospital, Cheongju, Korea, Republic of (South), ²Department of Health Informatics and Management, College of Medicine, Chungbuk National University, Cheongju, Korea, Republic of (South)
Background/Purpose: Gout results from an increased body pool of urate that occurs with hyperuricemia. Although urate-lowering therapy (ULT) is beneficial to prevent gout attack, current…
Abstract Number: 1130 • 2018 ACR/ARHP Annual Meeting
Chronic Risk Factors for Recurrent Gout Flares Among Established Gout Patients: A Prospective Cohort Analysis
Yuqing Zhang¹, Jie Wei², Chio Yokose², Sharan K. Rai^3,4 and Hyon K. Choi², ¹Department of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA, ²Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA, ³Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA, ⁴Graduate School of Arts and Sciences, Harvard University, Cambridge, MA
Background/Purpose: Understanding the risk factors for recurrent flares among established gout patients is directly relevant to clinical care; however, relevant data are scarce. A previous…
Abstract Number: 1284 • 2018 ACR/ARHP Annual Meeting
Initial Pegloticase Serum Levels Predict Persistent Responsiveness in Patients with Chronic Refractory Gout
Kenneth Saag¹, Mitchell Feinman², Herbert S. B. Baraf³, Roy Fleischmann⁴, Arthur Kavanaugh⁵ and Peter E. Lipsky⁶, ¹Division Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²ACME Research, LLC, Orangeburg, SC, ³Arthritis and Rheumatism Associates, Wheaton, MD, ⁴Metroplex Clinical Research Center, University of Texas Southwestern Medical Center, Dallas, TX, ⁵University of California, San Diego, School of Medicine, La Jolla, CA, ⁶AMPEL BioSolutions, Charlottesville, VA
Background/Purpose: Pegloticase is a pegylated recombinant mammalian uricase approved for treatment of persons with chronic gout refractory to standard urate lowering therapy1. Despite an initial…
Abstract Number: 1285 • 2018 ACR/ARHP Annual Meeting
Comparision of Urate Burden in Well and Poorly Controlled Gout Patients: A Dual-Energy CT Study
Min Kyung Chung¹, Hyeran Hyun², Ji Young Hwang² and Jisoo Lee¹, ¹Division of Rheumatology, Department of Internal Medicine, Ewha Womans University School of Medicine, Seoul, Korea, Republic of (South), ²Department of Radiology, Ewha Womans University School of Medicine, Seoul, Korea, Republic of (South)
Background/Purpose: Dual-energy computed tomography (DECT) allows sensitive and quantative detection of monosodium urate (MSU) crystals in patients with gout. Although its usefulness in diagnosing gout…
Abstract Number: 1980 • 2018 ACR/ARHP Annual Meeting
Comprehensive Association Analysis between Rare and Common ABCG2 Variants and Gout Susceptibility
Hirotaka Matsuo¹, Toshihide Higashino¹, Tappei Takada², Hirofumi Nakaoka³, Yu Toyoda⁴, Blanka Stiburkova⁵, Hiroshi Nakashima⁶, Seiko Shimizu¹, Makoto Kawaguchi⁷, Akiyoshi Nakayama⁸, Yuka Aoki¹, Misaki Ishino¹, Yusuke Kawamura¹, Kenji Wakai⁹, Rieko Okada¹⁰, Tatsuo Hosoya¹¹, Kimiyoshi Ichida¹², Hiroshi Ooyama¹³, Hiroshi Suzuki², Ituro Inoue³, Tanya J. Major¹⁴, Tony R. Merriman¹⁴ and Nariyoshi Shinomiya¹, ¹Department of Integrative Physiology and Bio-Nano Medicine, National Defense Medical College, Tokorozawa, Japan, ²Department of Pharmacy, The University of Tokyo Hospital, Faculty of Medicine, The University of Tokyo, Tokyo, Japan, ³Division of Human Genetics, Department of Integrated Genetics, National Institute of Genetics, Mishima, Japan, ⁴Department of Pharmacy, The University of Tokyo Hospital, Faculty of Medicine,, The University of Tokyo, Tokyo, Japan, ⁵Department of Pediatrics and Adolescent Medicine, Charles University and General University Hospital in Prague, First Faculty of Medicine, Prague, Czech Republic, ⁶Department of Preventive Medicine and Public Health, National Defense Medical College, Tokorozawa, Japan, ⁷National Defense Medical College, Tokorozawa, Japan, ⁸Dept Integrative Physiol, National Defense Medical College, Tokorozawa, Japan, ⁹Nagoya University Graduate School of Medicine, Nagoya, Japan, ¹⁰Department of Preventive Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan, ¹¹Division of Kidney and Hypertension, Department of Internal Medicine, Jikei University School of Medicine, Tokyo, Japan, ¹²Department of Pathophysiology, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan, ¹³Ryougoku East Gate Clinic, Tokyo, Japan, ¹⁴University of Otago, Dunedin, New Zealand
Background/Purpose: We have reported that ABCG2 has an important role in both renal and intestinal urate excretion and these common variants as rs72552713 (Q126X) and…
Abstract Number: 2205 • 2018 ACR/ARHP Annual Meeting
Initial Phase 2 Clinical Data of SEL-212 in Symptomatic Gout Patients: Measurement of Dissolution of Urate Deposits Associated with Monthly Dosing of a Pegylated Uricase (Pegadricase) with Svp-Rapamycin By Dual Energy Computed Tomography
Rehan Azeem¹, Earl Sands¹, Lloyd Johnston², Wesley DeHaan Ph.D.², Alan J. Kivitz³, Takashi Kei Kishimoto², Justin Park¹ and Savvas Nicolaou⁴, ¹Selecta Biosciences, Inc, Watertown, MA, ²Selecta Biosciences, Watertown, MA, ³Altoona Center for Clinical Research, Duncansville, PA, ⁴Radiology, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Pegylated uricases are therapies for treatment of severe chronic gout, particularly for rapid resolution of tophi. However, uricases are limited by induction of anti-drug…
Abstract Number: 2238 • 2018 ACR/ARHP Annual Meeting
Non-Coding Urate-Associated Variants Function in a Conserved Lincrna Regulatory Domain That Alters MAF transcription
Megan Leask¹, Tony R. Merriman¹, Amy Dowdle¹, Hamish Salvesen¹, Ruth Topless¹, Tayaza Fadason², Wenhua Wei¹, William Schierding², Justin O'Sullivan² and Julia Horsfield¹, ¹University of Otago, Dunedin, New Zealand, ²University of Auckland, Auckland, New Zealand
Background/Purpose: Genome-wide association studies (GWAS) have revealed that the large majority of disease-associated single nucleotide polymorphisms (SNPs) are located in the non-coding regions of the…
Abstract Number: 2253 • 2018 ACR/ARHP Annual Meeting
Cardiovascular Disease, Other Purported Risk Factors, and Allopurinol-Associated Severe Cutaneous Adverse Reactions: A General Population-Based Cohort Study
Na Lu¹, Chio Yokose², Hui Xie^1,3, Gloria Li¹, Sharan K. Rai^4,5, Seoyoung C. Kim⁶ and Hyon K. Choi², ¹Arthritis Research Canada, Richmond, BC, Canada, ²Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA, ³Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada, ⁴Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA, ⁵Graduate School of Arts and Sciences, Harvard University, Cambridge, MA, ⁶Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
Background/Purpose: A recent US Medicaid study found that in addition to certain races (Asians and Blacks), older age, female sex, chronic kidney disease (CKD), and…
Abstract Number: 2898 • 2017 ACR/ARHP Annual Meeting
New Mouse Model of Gout Risk Variant, ABCG2 Q141K, Reveals Unexpectedly Severe Molecular and Functional Defect in ABCG2 Mediated Intestinal Uric Acid Secretion
Kazi M. Hoque and Owen M. Woodward, Physiology, University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: Gout is a common arthritic disease resulting from deposition of monosodium urate crystals in joints and is a consequence of having elevated circulating uric…
Abstract Number: 1106 • 2017 ACR/ARHP Annual Meeting
Association between ABCG2 rs2231142 and Poor Response to Allopurinol: Replication and Meta-Analysis
Mary Wallace¹, Rebecca Roberts², Payal Nanavati³, Jeffrey N Miner³, Nicola Dalbeth⁴, Ruth Topless⁵, Tony R. Merriman⁶ and Lisa K. Stamp⁷, ¹Surgical Sciences, University of Otago, Dunedin, New Zealand, ²University of Otago, Dunedin, New Zealand, ³Ardea Biosciences, San Diego, CA, ⁴University of Auckland, Auckland, New Zealand, ⁵Department of Biochemistry, University of Otago, Dunedin, New Zealand, ⁶Biochemistry Dept, PO Box 56, University of Otago, Dunedin, New Zealand, ⁷University of Otago, Christchurch, New Zealand
Background/Purpose: Allopurinol is the most widely used urate-lowering drug. However, some patients treated with allopurinol do not achieve serum urate (SU) treatment target of <6mg/dl,…
Abstract Number: 1110 • 2017 ACR/ARHP Annual Meeting
Clinical Features and Risk of Recurrent Attack in Gout Patients According to Serum Urate Levels during an Acute Gout Attack
Jung Sun Lee¹, Seokchan Hong², Oh Chan Kwon², Byeongzu Ghang², Wook Jang Seo³, Doo-Ho Lim⁴, Yong-Gil Kim², Chang Keun Lee² and Bin Yoo², ¹Internal medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, Republic of (South), ²Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, Republic of (South), ³Seoul Veterans Hospital, Seoul, Korea, Republic of (South), ⁴Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Ulsan University Hospital, Ulsan, Korea, Republic of (South)
Background/Purpose: To investigate the clinical features and risk of gout recurrence in patients with normouricemia during an acute attack Methods: This study was conducted in…
Abstract Number: 1114 • 2017 ACR/ARHP Annual Meeting
Effects of Diacerein Controlled Release Tablets in Serum Uric Acid Reduction in Treating Subjects with Gout
Ying-Chou Chen Sr.¹, Shih-Chueh Chen², Chung-Tei Chou³, Carl Brown⁴, Jing-Yi Lee⁴, Wei-Shu Lu⁵ and Chang Youh Tsai⁶, ¹Division of Rheumatology, Allergy and Immunology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung County, Taiwan, ²Department of Endocrinology, Cheng Ching General Hospital, Taichung, Taiwan, ³Division of Allergy-Immunology-Rheumatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ⁴Medical Research, TWi Biotechnology, Inc., Taipei, Taiwan, ⁵TWi Biotechnology, Inc., Taipei, Taiwan, ⁶Division of Allergy- Immunology- Rheumatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
Background/Purpose: The goal of gout treatment is to reduce serum uric acid (sUA) concentrations below the urate solubility limit. Diacerein is known as an oral…
Abstract Number: 1123 • 2017 ACR/ARHP Annual Meeting
Random Urinary Uric Acid/Creatinine Ratio Is Useful in the Estimation of 24-Hour Urine Uric Acid Excretion in Patients with Gout
Sang Tae Choi¹, Seong-Jin Moon² and Eun-Jin Kang³, ¹Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea, Republic of (South), ²Internal Medicine, Catholic Kwandong University College of Medicine, Incheon, Korea, Republic of (South), ³Internal Medicine, Busan Medical Center, Busan, Korea, Republic of (South)
Background/Purpose: Gout is a chronic inflammatory disease resulted from hyperuricemia. The measurement of 24-hour urinary uric acid excretion is frequently used to evaluate disease status…
Abstract Number: 1141 • 2017 ACR/ARHP Annual Meeting
Initial Results of a Clinical Study to Determine Whether a Tolerizing Regimen of Pegloticase Can Increase the Frequency of Subjects Having Sustained Lowering of Serum Urate
Kenneth Saag¹, Mitchell Feinman², Alan J. Kivitz³, Herbert S. B. Baraf⁴, Roy Fleischmann⁵, Arthur Kavanaugh⁶ and Peter E. Lipsky⁷, ¹Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ²ACME Research, LLC, Orangeburg, SC, ³Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA, ⁴Center for Rheumatology and Bone Research, Wheaton, MD, ⁵Southwestern Medical Center at Dallas, University of Texas, Dallas, TX, ⁶Medicine, University of California, San Diego, La Jolla, CA, ⁷AMPEL BioSolutions, LLC, Charlottesville, VA
Background/Purpose: Pegloticase is a pegylated recombinant mammalian uricase approved for treatment of persons with chronic gout refractory to standard urate lowering therapy1. Despite initial reduction…
Abstract Number: 1145 • 2017 ACR/ARHP Annual Meeting
Effectiveness of a Multidisciplinary Gout Clinic on Timely Achievement of Serum Uric Acid Goals
Kah Mun Cheong¹, Archana Vasudevan², Melonie Sriranganathan², Elena Lee¹, Serene Yeow¹ and Prista Ramskay¹, ¹Department of Pharmacy, Changi General Hospital, Singapore, Singapore, Singapore, ²Department of Medicine, Changi General Hospital, Singapore, Singapore, Singapore
Background/Purpose: The concept of a multidisciplinary gout clinic is relatively new in Singapore. Changi General Hospital launched such a clinic in 2014 to provide treat-to-target…

1
2
3
…
5
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].